|Articles|February 1, 2005
Topping tamoxifen as 1st-line Rx for postmenopausal breast Ca
Aromatase inhibitors should replace tamoxifen as the first choice for preventing recurrence of breast cancer in postmenopausal women with localized hormone receptor-positive disease, according to this large-scale study.
Advertisement
Newsletter
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Advertisement
Latest CME
Advertisement
Advertisement












